Next Article in Journal
Mutual Inhibition of Antithrombin III and SARS-CoV-2 Cellular Attachment to Syndecans: Implications for COVID-19 Treatment and Vaccination
Previous Article in Journal
The Clinical Significance of CRNDE Gene Methylation, Polymorphisms, and CRNDEP Micropeptide Expression in Ovarian Tumors
Previous Article in Special Issue
Peptides Used for Heavy Metal Remediation: A Promising Approach
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 14
10.3390/ijms25147533
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Restoring Skeletal Muscle Health through Exercise in Breast Cancer Patients and after Receiving Chemotherapy

by
Inês Aires
1,2,
José Alberto Duarte
3,4,
Rui Vitorino
5,*,
Daniel Moreira-Gonçalves
3,
Paula Oliveira
2 and
Rita Ferreira
1
1
LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
2
CITAB, Inov4Agro, University of Trás-os-Montes and Alto Douro (UTAD), Quinta de Prados, 5000-801 Vila Real, Portugal
3
CIAFEL, and Laboratory for Integrative and Translational Research in Population Health (ITR), Faculty of Sports, University of Porto (FADEUP), 4200-450 Porto, Portugal
4
UCIBIO-Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal
5
iBiMED, Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(14), 7533; https://doi.org/10.3390/ijms25147533
Submission received: 21 May 2024 / Revised: 28 June 2024 / Accepted: 4 July 2024 / Published: 9 July 2024
(This article belongs to the Special Issue Innovative Molecular Strategies in Biomedicine)
Browse Figures
Versions Notes

Abstract

:
Breast cancer (BC) stands out as the most commonly type of cancer diagnosed in women worldwide, and chemotherapy, a key component of treatment, exacerbates cancer-induced skeletal muscle wasting, contributing to adverse health outcomes. Notably, the impact of chemotherapy on skeletal muscle seems to surpass that of the cancer itself, with inflammation identified as a common trigger for muscle wasting in both contexts. In skeletal muscle, pro-inflammatory cytokines modulate pathways crucial for the delicate balance between protein synthesis and breakdown, as well as satellite cell activation and myonuclear accretion. Physical exercise consistently emerges as a crucial therapeutic strategy to counteract cancer and chemotherapy-induced muscle wasting, ultimately enhancing patients’ quality of life. However, a “one size fits all” approach does not apply to the prescription of exercise for BC patients, with factors such as age, menopause and comorbidities influencing the response to exercise. Hence, tailored exercise regimens, considering factors such as duration, frequency, intensity, and type, are essential to maximize efficacy in mitigating muscle wasting and improving disease outcomes. Despite the well-established anti-inflammatory role of aerobic exercise, resistance exercise proves equally or more beneficial in terms of mass and strength gain, as well as enhancing quality of life. This review comprehensively explores the molecular pathways affected by distinct exercise regimens in the skeletal muscle of cancer patients during chemotherapy, providing critical insights for precise exercise implementation to prevent skeletal muscle wasting.

1. Introduction

Breast cancer (BC) is the most commonly diagnosed type of cancer in women worldwide [1]. With increased life expectancy, improved diagnostic techniques and cancer registration, BC incidence has been on the rise globally. BC represents a vast and heterogeneous group of tumors, each with distinct cellular and molecular features, leading to varying clinical presentations and responses to therapy [2]. Tailoring treatment approaches to the specific subtype of BCa is crucial, as each subtype exhibits a unique response to therapy. While targeted therapies have emerged, cytotoxic drugs remain the most effective means of treating BC metastasis [3]. BC patients typically receive chemotherapy regimens that include antineoplastic drugs, such as the combination chemotherapy regimen with cyclophosphamide, methotrexate, and 5-fluorouracil, anthracyclines (doxorubicin, epirubicin), and taxanes (paclitaxel, docetaxel). These regimens can be administrated alone or concurrently with radiotherapy, surgery, and/or hormonal therapy [4]. However, these antineoplastic agents also affect normal cells, leading to chemotherapy’s well-known side effects such as secondary leukemia and cardiomyopathy, which can result in congestive heart failure [5]. Skeletal muscle wasting, a side effect of cancer and chemotherapy, is frequently underestimated, despite its significant impact on the quality of life of patients, wherein fatigue is recognized to reduce patient tolerance to cancer therapies [6].
In the pursuit of more effective and less debilitating treatments to complement the multimodal management of BC patients, non-pharmacological therapeutic interventions have been explored, such as diet supplementation [7,8] or physical exercise [9]. In fact, the hypothesis that physical exercise can offer protection against BC dates back to the 1980s [10]. Several potential molecular mechanisms linking physical activity and BC have been proposed, including alterations in the serum levels of sex hormones, insulin, and adipokines, along with changes in molecular pathways associated with inflammation and oxidative stress within skeletal muscle [11]. Nonetheless, the molecular pathways underlying skeletal muscle wasting remain unclear, particularly in the realm of BC chemotherapy. To gain insights into the role of exercise in the management of BC, the VOSviewer tool was used to visualize and analyze bibliometric data on the co-occurring terms “cancer”, “chemotherapy”, and “exercise”. The results presented in Figure 1 highlight that exercise primarily serves to improve patients’ quality of life. Interestingly, certain aspects have received limited attention in research, e.g., cancer- and chemotherapy-related comorbidities such as skeletal muscle wasting. Several factors are also involved in this intricate interplay, which, despite their importance, they often only occupy a peripheral position in the network. These factors encompass exercise intensity, duration, and type, the specific chemotherapy regimen, and individual patient characteristics.
Therefore, a comprehensive understanding of the role that these nuanced factors play in the broader network of exercise in BC could significantly advance the concept of “Exercise is Medicine”. This review aims to overview how different exercise programs may counteract the metabolic adaptations underlying BC and/or chemotherapy-induced muscle wasting and holds the prospect of defining guidelines for prescribing tailored exercise programs in the cancer setting.

2. Tailoring Exercise Programs to Address Breast Cancer-Related Body Wasting

Research on the complex interplay between cancer and chemotherapy-induced muscle wasting has supported the beneficial effects of diverse exercise programs. However, as the concept of “Exercise is Medicine” gains increasing recognition, it becomes crucial to understand how to maximize its health benefits. Each patient has specific needs, being challenging to implement “one-size fits all” training program. However, it is extremely difficult to prescribe and implement an exercise training program tailored to the specific needs of each individual. As a result, exercise programs that aim to address cancer-related outcomes, such as fatigue, anxiety, and quality of life (QoL), have shown beneficial effects in clinical trials and are usually employed. Nevertheless, distinct exercise programs have yielded comparable health benefits. For instance, a moderated aerobic training routine performed at least three times per week for a minimum of 30 min [12], or a resistance training program conducted at least twice a week with a minimum of two sets of 8–15 repetitions [13], have shown comparable outcomes. Furthermore, combined exercise training, twice a week for 80–90 min, has demonstrated similar effectiveness [12]. Still, not all patients benefit equally from the same types of exercise regimens. Addressing this challenge requires a multifaceted approach when prescribing an exercise program that takes into account a spectrum of factors related to the oncologic condition such as disease stage, as well as factors beyond the oncologic condition. These factors, including age, sleep schedule, nutrition, environment, and physical and mental condition, must all be thoughtfully considered in exercise prescription [14].
When establishing an exercise routine, the extent of skeletal muscle wasting must be carefully evaluated. Although both cancer- and chemotherapy-induced muscle wasting may lead to significant weight loss, this change in weight does not necessarily align with alterations in body composition [15]. Patients undergoing chemotherapy may be more prone to severe muscle wasting compared to those experiencing muscle loss solely due to cancer. Patient’s age plays a crucial role in shaping personalized exercise programs, especially in older individuals facing sarcopenia [16,17,18,19]. Additionally, it is worth recognizing that BC patients, including younger ones, may undergo menopause. Those may often experience a more pronounce muscle wasting and may not respond to exercise as effectively as premenopausal ones [20]. Patients experiencing severe muscle wasting or in advanced cancer stages might not be suitable candidates for exercise programs that require a performance level capable of discerning measurable benefits [21]. In fact, determining the optimal timing for prescribing exercise to counteract muscle wasting may be a challenge. While physical activity undeniably offers significant health benefits and is essential across various contexts, its implementation in cancer patients presents unique challenges, due to differences in disease stages that may affect patients’ performance. Ideally, identifying patients at higher risk of developing muscle wasting and intervening at the earliest possible stage would be the ultimate goal. However, predicting and identifying these deleterious muscle wasting conditions may prove challenging [22]. Nevertheless, when feasible, the early initiation of exercise before muscle wasting becomes more pronounced can serve multiple purposes. During these initial phases, exercise may primarily address cancer-induced comorbidities or mitigate the toxic effects associated with the early stages of chemotherapy-induced muscle wasting [5]. In more advanced stages, if feasible, lower impact exercises should be prioritized to prevent exceeded fatigue, potentially compromising overall health and treatment effectiveness during therapy [23].

Exercise Counteracts Breast Cancer- and Chemotherapy-Induced Body Wasting

Although not as prevalent in BC as in other cancer types like pancreatic, gastric, and lung cancer, body weight loss due, at least in part, to muscle wasting can occur in advanced-stage BC patients [24]. This skeletal muscle loss is a central component of cachexia, a syndrome that significantly contributes to poor performance status and increased mortality among cancer patients [25]. Furthermore, chemotherapy can exacerbate the skeletal muscle atrophy, which is linked to a poor prognostic, and increased mortality and morbidity [25]. Importantly, exercise interventions have demonstrated promise in alleviating muscle atrophy and enhancing the overall well-being of BC patients [26]. However, to maximize the benefits of exercise in the BC setting, it is crucial to gain a better comprehension of its role on the interplay between cancer- and chemotherapy-induced muscle wasting. Such understanding can be achieved through, for example, a comprehensive comparison of the whole-body and skeletal muscle remodeling promoted by various exercise protocols. In fact, it becomes evident that even when engaging in the same type of exercise, minor variations in parameters such as duration or intensity can yield distinct outcomes [27,28,29,30]. Therefore, acknowledging the molecular mechanisms that govern the interplay between distinct exercise programs and BC-induced muscle wasting will pave the way for the development of exercise regimens tailored for BC patients. However, there is a scarcity of studies examining whole-body adaptations in BC patients undergoing chemotherapy and participating in exercise programs, with, to our knowledge, only six studies dedicated to the evaluation of skeletal muscle remodeling. When such investigations do take place, they typically rely on imaging-based approaches, e.g., L3 muscle index based on computerized tomography and functional tests (e.g., assessment of muscle strength and fatigue), with few studies including muscle biopsies (Table 1). In fact, muscle biopsies were conducted in merely two studies [29,30], and molecular data were only reported in one [29]. The absence of muscle biopsy data limits our understanding of the molecular mechanisms of skeletal muscle adaptation to exercise in BC, thereby limiting the prescription of exercise in therapeutic plans due to the lack of robust molecular evidence.
Exercise, regardless of the regimen, has been reported to lower fatigue, depression, and anxiety, improving the overall self-esteem and quality of life of BC patients [41]. When assessing the impact on quality of life, all types of exercise have shown improvements (Table 1). Hence, some studies have included control groups that were also encouraged to follow an exercise routine and were provided with an exercise protocol, albeit without supervision after the post-intervention assessments [27,30]. The majority of the exercise protocols were performed under supervised conditions, which is acknowledged as a key factor for the effectiveness of the exercise regimens [38]. Nonetheless, including exercise in a therapeutic plan for BC patients presents significant challenges. The lack of detailed molecular knowledge about exercise effects in cancer context frequently raises doubts about its potential effectiveness among clinicians and patients. Furthermore, BC patients frequently lack motivation due to increased fatigue. In those cases, group classes can be more beneficial, as they are more enjoyable [42,43] and have shown high attendance rates among women [42,44]. However, the primary limitation may be severe muscle wasting and other cancer comorbidities, which may coincide with more advanced disease stages and aggressive treatments, potentially hindering patients’ capacity to engage in exercise programs [45].
In the BC setting, while reduced food intake can contribute to muscle loss, the hypermetabolic state that increases resting energy expenditure (REE) in patients results in involuntary body weight loss, a hallmark of cachexia [46,47]. BC patients commonly exhibit lower lean body mass levels, as the shifting in metabolism, marked by an increase of catabolic processes while anabolic ones are downregulated, is primarily associated with tumor metabolism [48,49]. In fact, despite the pivotal role of the imbalance between protein synthesis and proteolysis in driving muscle wasting, the well-known “Warburg effect” may also contribute to the increase of REE, particularly in more advanced stages of cancer [49,50]. Additionally, the early menopause experienced by younger BC patients under treatment may not only affect the quality of life but also the body composition. Post-menopause women, characterized by low estrogen levels and an often decline in overall physical activity, may undergo an increase in body fat, particularly visceral adipose tissue [51]. Premenopausal women with BC following chemotherapy also experience a decrease in lean body mass, akin to what is observed in postmenopausal women [16,52]. Exercise, particularly resistance training protocols, have demonstrated significant gains in lean body mass [27,28], making them advisable for BC. Interestingly, some aerobic programs have also shown some lean body mass gains [27,28]. An increase in lean body mass can counteract muscle wasting, yet it might not necessarily result in a rise in REE. In cancer patients, the overall muscle mass will still be lower compared to a healthy individual. In those cases, and considering the overall health condition, the focus is primarily preserving the muscle mass rather than drastically increasing it [53]. Lean body mass can also have an impact on chemotherapy toxicity [54]. Chemotherapy dosages are typically determined based on body surface area (m2), considering solely the height and weight. However, if two patients, for example, share identical measurements, the one with higher lean body mass will likely experience fewer chemotherapy-related toxicities. Hence, an exercise protocol that enhances lean body mass levels becomes a valuable therapeutic strategy in this context [27,28]. Exercise, particularly resistance training protocols have demonstrated significant gains in lean body mass [27,28,37]. Interestingly, some aerobic programs have also shown some gains [27,28].

3. Exercise Training Counteracts Cancer- and/or Chemotherapy-Induced Muscle Wasting: The Molecular Targets

There are few studies addressing the molecular alterations underlying cancer- and chemotherapy-induced skeletal muscle wasting in humans [29,30], which may be due, in part, to ethical constraints on taking muscle biopsies from BC patients. Indeed, the diagnosis of muscle wasting in BC patients is often underestimated, and even when it is recognized, it usually occurs at advanced stages of the disease, which poses a greater challenge for its effective clinical management. Moreover, determining the extent of muscle atrophy in cancer patients is a difficult task, as the decrease in total body weight is not always accompanied by the loss of skeletal muscle mass [15]. Animal models offer the advantage of allowing a comprehensive examination of the remodeling of whole muscle tissue in response to cancer and/or therapy. This analysis can be performed without potential biases from factors such as diet or unrelated therapies [26,55]. However, to our knowledge, there are no studies that have investigated the impact of exercise on the interplay between BC and chemotherapy in animal models of mammary tumorigenesis. Nevertheless, it is possible to gain insights into the therapeutic effect of exercise on the molecular mechanisms underlying cancer- and chemotherapy-induced muscle wasting by focusing on research developed exclusively in the context of BC or chemotherapy. Translation of the molecular findings underlying muscle wasting from other cancer models requires more cautious interpretation, as evidence of a direct link to BC remains hypothetical until further dedicated research is conducted.

3.1. Exercise-Induced Remodeling of Muscle Fiber Phenotype in Cancer-Induced Muscle Wasting

Research in animal models of BC has shown muscle atrophy in both muscle fibers type I and type II [56]. However, the glycolytic fast-twitch type II fibers seem to be more prone to wasting [57], characterized by an accentuated decrease of fiber size [26]. Following carboplatin treatment, BC animals exhibited a decrease of all muscles mass, although only tibialis anterior showed a reduction in fiber cross-sectional area (CSA) [58]. Similar outcomes were observed in rats treated with doxorubicin, although healthy animals were enrolled and not those with BC or other types of cancer [59]. The results remained consistent across other types of cancer, suggesting that the decrease in fiber CSA, and consequently muscle atrophy, may not be linked to cancer type, but rather to tumor growth and chemotherapy administration [60]. This association may raise questions about the underlying mechanisms, which have been proposed to involve inflammation, increased skeletal muscle oxidative stress, mitochondrial dysfunction, and apoptosis [26,61,62].
Distinct muscles respond differently to various types of exercise in wasting conditions. In doxorubicin-treated healthy animals, no differences in soleus mass were observed following aerobic exercise (progressive treadmill training for 2 weeks) [36] or resistance (jump to reach food and water with a progressively increasing height (until 8 inches) for 2 weeks, representing ~70% VO2max) [35]. However, for the extensor digitorum longus (EDL) muscle the same resistance exercise program was shown to promote mass gain [35]. In aerobic exercise protocols, the outcomes reported in the literature depend on the protocol’s duration. While a progressive treadmill protocol performed for 2 weeks yielded the same results as the resistance exercise protocol, animals in a 10-week protocol (progressive treadmill starting at 20 m/min, 20 min/day and increasing until 30 m/min, 60 min/day, 18° incline, representing ~75% VO2max) showed a decrease in EDL mass [35,36]. Notably, and although the resistance exercise-induced hypertrophy is more prominent in glycolytic type II fibers, an increase in fiber CSA has been reported in all fiber types, resulting in an overall enhancement of muscle force [63,64]. In contrast, aerobic exercise promotes a shift towards increased recruitment of oxidative type I fibers [61]. This fiber switch is linked to metabolic alterations towards an oxidative phenotype [65,66,67], being better positioned to alleviate muscle fatigue rather than increase overall muscle force [35].

3.2. Exercise Counteracts Oxidative Stress and Inflammation on Cancer and Chemotherapy-Induced Muscle Wasting

Chemotherapy-induced oxidative stress has been extensively hypothesized as a key molecular mechanism underlying skeletal muscle wasting in the context of cancer treatment. This increase in oxidative stress seems to be linked to a decrease in the content of antioxidant systems triggered by doxorubicin, a phenomenon also observed in cardiac cells [68]. Furthermore, given the high metabolic activity of skeletal muscle, there is an increased generation of reactive oxygen species (ROS), primarily associated with mitochondrial dysfunction, which is marked by decreased mitochondrial respiratory chain activity and ATP synthesis [6,59,69,70]. Doxorubicin-related production of ROS occurs mainly at electron transport chain (ETC) complex I, where this drug undergoes a single-electron reduction reaction. The high affinity of doxorubicin for the inner mitochondrial membrane, particularly for the phospholipid cardiolipin, facilitates its binding and subsequent reduction. This reaction results in the removal of electrons from the ETC, disrupting oxidative phosphorylation and ATP production [71,72]. The consequent decline in the ATP generation will ultimately lead to skeletal muscle’s metabolism disruption, resulting in muscle weakness [73]. Moreover, the increased ROS levels induced by doxorubicin and other antineoplastic drugs may trigger lipid peroxidation, which can disturb the integrity and function of the cell membrane, with impact on muscle contractile function [74]. ROS may also impair the contractile process by interfering with intracellular and mitochondrial Ca2+ homeostasis, leading to impaired muscle force generation and contractility [75,76]. Moreover, the elevation in ROS levels can modulate signaling pathways, such as NF-κB signaling pathways, which promote muscle protein breakdown and inhibit muscle protein synthesis [76]. In fact, several proteolytic systems, such as calpains, caspases, the ubiquitin-proteasome system (UPS), and autophagy, have been reported to be activated in skeletal muscle in response to chemotherapy, stimulating the STAT3 pathway and Akt-mediated phosphorylation of FOXO3, leading to the overexpression of ubiquitin E3 ligases on soleus and gastrocnemius muscles [32,77,78] (Figure 2).
The role of exercise in oxidative stress has caught significant attention because exercised-induced increase in ROS may activate signaling pathways and promote skeletal muscle adaptation to exercise [79]. ROS signaling plays a role in modulating specific pathways, such as activating NF-kB and MAPK. It has been proposed that ROS may trigger adaptive responses through these redox-sensitive signaling pathways to maintain cellular oxidant-antioxidant homeostasis during exercise. In short time periods, ROS activates signaling pathways that modulate cellular adaptations, protecting against future stresses. In longer time periods, ROS signaling may result in the chronic activation of pathways that promote proteolysis, potentially leading to cell death [80]. However, the exercise-induced skeletal muscle adaptation mediated by ROS extends beyond these pathways, as it has been proposed that ROS production is necessary for peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) expression, a crucial player in aerobic exercise adaptation [81]. Hence, given the pivotal role of ROS signaling, one could anticipate that engaging in exercise training may lead to an escalation in ROS levels in the skeletal muscle of BC patients, particularly when baseline ROS levels are already elevated. However, endurance exercise (progressive treadmill 5 days/week, increasing 10 min/day until 60 min/day at 30 m/min, for 2 weeks, representing ~70% VO2max) was reported to increase the expression of antioxidant enzymes such as superoxide dismutase, and glutathione peroxidase in the soleus of doxorubicin-treated rats while simultaneously decreasing the activity of calpains and caspase-3 [34], potentially counteracting the muscle atrophy induced by this anticancer drug [26].
On the other side, auto(mito)phagy is also activated in inflammatory conditions and associated with metabolism disruption and skeletal muscle mass loss [82,83,84]. This highly selective and regulated process involves specific signals such as p62, Bnip3, Nbr1, which are composed of a cargo-binding domain that recognizes and attaches to organelles, and a LC3-interacting region (LIR) responsible for recruiting and binding to autophagosome membrane proteins [85]. Increased auto(mito)phagy leads to muscle atrophy, while a decrease in this process may result in muscle weakness and myofibers degeneration [86,87]. Notably, in animals treated with doxorubicin, there was a decrease in the expression of beclin-1 during endurance exercise (progressive treadmill 5 days/week, increasing 10 min/day until 60 min/day at 30 m/min, for 2 weeks, representing ~70% VO2max) compared to sedentary ones [34]. In doxorubicin-treated rats submitted to another aerobic protocol (treadmill 5 days/week, 40–60 min/day, at 60% maximum speed), the autophagy genes were analyzed concurrently with STAT3, which was regulated by the pro-inflammatory IL-6, and decreased levels were found following exercise [32,77]. Additionally, in mice inoculated with Colon26 carcinoma cells, other endurance protocol (motorize wheel, 5 days/week, 5 m/min for 15 min, increasing 11 m/min for 45 min) was shown to decrease Bnip3 levels. Concurrently, the decrease in autophagy was accompanied by an increase in mitochondrial function, as evidenced by the upregulation in Mfn2 gene expression, indicating fusion, and no changes in Fis1 and Mfn1 gene expression, indicating fission [33]. As for resistance training (ladder-climbing protocol 3 days/week, load at 75% body-weight that increased according to performance), in mice inoculated with breast carcinoma cells, a decrease in autophagy proteins was observed, especially LC3B-II and beclin-1 [88] (Figure 2). Under normal conditions, the auto(mito)phagy process helped maintaining a pool of healthy mitochondria by eliminating the defective ones [84]. Hence, in cancer settings, the observed exercise-induced decrease of auto(mito)phagy may reflect healthier mitochondria that do not need to be eliminated to avoid the toxicity of their accumulation [33].
Exercise training can promote an increase in circulating skeletal muscle-derived IL-6, known for its anti-inflammatory activity, as it inhibits the action of pro-inflammatory cytokines like TNF-α and promotes the synthesis of anti-inflammatory cytokines, particularly IL-10 [89]. The peak of anti-inflammatory IL-6 typically occurs at the end or shortly after exercise, followed by a rapid decline in its levels [90]. This peak is more pronounced in endurance exercise with longer duration, particularly when larger muscle groups are engaged. Interestingly, different effects are anticipated for distinct exercise intensities, with high-intensity exercise more effective at counteracting the effects of pro-inflammatory cytokines compared to low-intensity exercise [91]. Resistance exercise for 16 weeks (3 times/week,15 exe. 3 sets, 20 reps, increased weight if 20 reps are performed) was reported to decrease the circulating levels of inflammatory cytokines such as IL-6, TNF-α, IL-8, and IL-1, even in postmenopausal BC patients [92]. In fact, resistance exercise promoted a decrease in the expression of Toll-like receptor-4 (TLR-4) in monocytes/macrophages [93], diminishing the TLR-4-induced pro-inflammatory cytokines [94]. Thus, by reducing TLR-4 expression in monocytes/macrophages, resistance exercise may counteract cancer- and chemotherapy-induced muscle wasting. Aerobic exercise did not induce significant changes in TLR-4 expression in the gastrocnemius of doxorubicin-treated healthy animals [32], possibly reflecting no alterations in macrophage infiltration in skeletal muscle following treatment. On the other hand, combined exercise has demonstrated only a decrease in IL-6 levels in mice inoculated with Colon26 carcinoma cells or Lewis Lung carcinoma cells [67].

3.3. Metabolic Remodeling and Hormonal Influence on Skeletal Muscle Response to Exercise in Cancer Settings

Dysregulation of glucose metabolism has been observed in BC patients [95] and associated with the pro-inflammatory status that plays a critical role in the development of insulin resistance [96]. Exercise, particularly aerobic exercise due to its anti-inflammatory effect, may improve insulin sensitivity in skeletal muscle, with an impact on its metabolism. In fact, aerobic exercise has received more attention in the literature compared to resistance training in the management of muscle wasting associated to chronic diseases such as cancer. Endurance training has shown favorable effects on muscle insulin sensitivity through the modulation of GLUT4 and glycogen synthase expression, as well as glucose oxidation [97]. Regarding resistance exercise, no studies using animal models of cancer were found evaluating insulin sensitivity. However, resistance exercise seems to modulate insulin sensitivity in cancer patients by preserving or enhancing lean body mass [98,99]. While these results were initially demonstrated in diabetic patients, similar results were reported in BC patients [43]. However, it is important to highlight that these studies enrolled elderly cancer patients who may have already been experiencing age-related muscle loss, potentially introducing bias when evaluating the skeletal muscle outcomes related to cancer and chemotherapy [43,98,99].
Aerobic exercise induces significant metabolic remodeling in skeletal muscle, primarily characterized by the upregulation of the transcriptional cofactor PGC-1α, which plays a crucial role in mitochondrial biogenesis. PGC-1α promotes an oxidative phenotype and, consequently, a shift of fast-contracting fibers into slow-contracting ones. This metabolic energy sensor in skeletal muscle [100] protects against atrophy induced by age, disuse, and inflammation [101]. Other regulatory roles have been attributed to PGC-1α, such as the inhibition of FOXO3 and NF-kB signaling, providing a potential protective mechanism against muscle loss [31,34,100]. By inhibiting these pathways, voluntary physical activity in a running wheel was shown to promote the downregulation of atrogin-1 and MuRF1, E3 ligases from the UPS, in muscle tissue from mice [97], and 21–28 days of endurance exercise training (treadmill 5 days/week, 40–60 min, at 60% maximum speed) promoted the downregulation of NF-kB signaling in rats undergoing treatment with doxorubicin [32]. Aerobic exercise has also been associated with the upregulation of the insulin-like growth factor 1 (IGF-1)/PI3K/AKT/mTOR pathway [32,77], which was reported to be downregulated in the BC setting [58]. This pathway stimulates protein synthesis and muscle growth while simultaneously inhibiting FOXO3 transcriptional activity, thus decreasing the expression of E3 ligases [102] (Figure 2). Moreover, in rats inoculated with Walker-256 tumor cells, 52 days of resistance exercise (4–8 ladder climbs with 50%; 75%; 90%, and 100% maximal carrying capacity, 3 days/week) [103] was able to trigger protein synthesis, counteracting the increased proteolysis underlying cancer-induced muscle wasting [104]. This increase in protein synthesis may be mediated by mTOR pathway, which was observed to be upregulated following resistant exercise [103]. Notably, in one of the few molecular studies performed with BC patients undergoing chemotherapy and submitted to a combined exercise protocol (3 days/week, 90 min/day, 6 resistance exe plus ergometer bicycle), a significant increase in FOXO3, atrogin-1, and MuRF-1 expression was reported in vastus lateralis [29]. Nevertheless, immediately following resistance exercise, protein synthesis may be temporarily suppressed, which rapidly shifts moments after exercise [105]. These findings were reported in healthy fasted individuals, suggesting that the shift to anabolic metabolism was only promoted by exercise and not by feeding [105]. Even though an increase in IGF-1 signaling was shown after resistance exercise, there was no rise in the serum levels of this growth factor. Thus, it was proposed that the increased mechanical load induced by resistance exercise may activate IGF-1 signaling in skeletal muscle, which, in turn, induces the proliferation and differentiation of satellite cells, contributing to their activation and myonuclear accretion, as well as muscle mass gain [106] (Figure 2).
The changes in the levels of sex hormones accompanying BC can also impact muscle mass and function. Testosterone is known to directly activate mTOR pathway, resulting in increased protein synthesis and, eventually, muscle hypertrophy, in both type I and II muscle fibers [107]. Notably, some of the testosterone roles in male patients were not consistently reported in female ones, as the latter typically rely on estrogens to maintain skeletal muscle function [108]. Interestingly, estrogen seems to regulate fatigue and muscle contractile response in patients of both sexes. In fact, due to menopause, women often undergo a more pronounced and early decline in muscle strength compared to men [109]. However, in postmenopausal woman, progesterone may act similarly to testosterone, modulating muscle protein synthesis [110]. Moreover, estrogen may be implicated in enhancing skeletal muscle mass by promoting satellite cells activation and myonuclear accretion [111]. In BC patients, menopause is primarily associated with low estrogen levels, and these reduced levels are not as strongly associated with the adaptive changes promoted in muscle by resistance training compared to testosterone [112]. Different adaptations to resistance exercise were observed in healthy young women during different phases of the menstrual cycle, reporting different outcomes on muscle strength and power. In fact, these results showed that comparing luteal and follicular phase, the latter showed higher muscle gain and hypertrophy [113]. Similarly, in women performing any form of hormonal birth control, there were also reported diverse skeletal muscle outcomes [114]. Hence, this correlation underscores the importance of sex hormones fluctuations in resistance training induced adaptations and performance. Estrogen seems to improve overall muscular strength, whereas progesterone seems to negatively affect the muscle function in premenopausal women. Furthermore, it is important to acknowledge that in BC patients undergoing menopause, the low estrogen levels may lead to more subtle skeletal muscle outcomes and adaptations to resistance exercise training. However, and despite those changes in exercise adaptation, resistance training seemed to consistently increase overall muscle mass and strength [20].

4. Conclusions and Future Perspectives

Our review brings a novel perspective by focusing on muscle remodeling influenced by the interplay between BC, chemotherapy, and exercise, while examining the impact of different exercise programs. A spectrum of molecular mechanisms is responsible for muscle wasting in both cancer and chemotherapy, which can be mitigated to some extent by exercise training, thereby supporting its prescription. In BC, chemotherapy appears to exert a more pronounced impact on skeletal muscle remodeling than the cancer itself, leading to poorer health outcomes. Notably, inflammation is a common trigger for muscle wasting in both cancer and chemotherapy. Thus, the pathways modulated by pro-inflammatory cytokines play a key role in the imbalance between protein synthesis and breakdown, as well as in satellite cells’ activation and myonuclear accretion. Despite its recognized anti-inflammatory effects, the health benefits of aerobic exercise are equaled or even exceeded by resistance exercise in terms of increasing mass and strength and improving quality of life. Indeed, most studies that have investigated the therapeutic value of exercise training in BC patients undergoing chemotherapy have focused primarily on quality of life and functional parameters, with only a limited number of studies including molecular analyzes of skeletal muscle biopsies. Some investigations have been conducted in animal models; however, the interaction between chemotherapy and cancer in skeletal muscle remodeling remains understudied within the context of BC. In fact, the primary limitation of our study is the scarcity of research addressing the impact of exercise on BC and chemotherapy-induced muscle wasting. Therefore, to develop effective exercise regimens for BC patients at different stages, additional preclinical and clinical studies focused on muscle remodeling are essential.
Despite the recognized importance of skeletal muscle wasting in cancer management, it has received less attention compared to other organs such as the heart in response to cancer and chemotherapy. Therefore, it is crucial to undertake additional molecular research using animal models of BC subjected to various chemotherapy regimens. This research will help bridge existing knowledge gaps and provide a deeper insight into the skeletal muscle remodeling processes influenced by the interplay between BC and chemotherapy.
Moreover, future controlled clinical trials need to be conducted, enrolling BC patients at various disease stages and undergoing diverse exercise programs tailored to the individual condition of each patient. These trials should evaluate muscle wasting alongside cancer comorbidities to better understand muscle remodeling and maximize the benefits of exercise in managing BC patient’s health. This presents a significant challenge, given the diversity of cancer patients and the large cohorts required, as some BC patients may be unable or unwilling to participate in exercise programs. However, these clinical trials are crucial to produce guidelines that delineate personalized exercise regimens tailored to the individual needs of each BC patient. Furthermore, addressing barriers to implementing exercise in clinical practice, such as healthcare provider education, better patient motivation, and patients’ accessibility to structured exercise programs, should be the next step. Exercise has the potential to better manage cancer comorbidities and significantly improve the quality of life for BC patients. By reversing muscle mass loss and improving muscle quality, we anticipate better disease and treatment outcomes, considering the critical role of skeletal muscle in regulating overall health.

Author Contributions

Conceptualization: I.A. and R.F.; writing—original draft preparation: I.A.; formal analysis and investigation: I.A., D.M.-G. and R.V.; writing—review and editing: J.A.D., P.O. and R.F.; supervision: P.O. and R.F. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

This work was supported by LAQV (LA/P/0008/2020 DOI 10.54499/LA/P/0008/2020, UIDP/50006/2020 DOI 10.54499/UIDP/50006/2020 and UIDB/50006/2020 DOI 10.54499/UIDB/50006/2020), iBiMED (UIDB/04501/2020 and POCI-01-0145-FEDER-007628), CIAFEL (UIDB/00617/2020) and CITAB (UIDB/04033/2020) research units projects through national founds by the Portuguese Foundation for Science and Technology (FCT)/Ministry of Science, Technology and Higher Education (MCTES).

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Key, T.J.; Verkasalo, P.K.; Banks, E. Epidemiology of Breast Cancer. Lancet Oncol. 2001, 2, 133–140. [Google Scholar] [CrossRef] [PubMed]
  2. Pernas, S.; Tolaney, S.M. HER2-Positive Breast Cancer: New Therapeutic Frontiers and Overcoming Resistance. Ther. Adv. Med. Oncol. 2019, 11, 1758835919833519. [Google Scholar] [CrossRef]
  3. Bailleux, C.; Eberst, L.; Bachelot, T. Treatment Strategies for Breast Cancer Brain Metastases. Br. J. Cancer 2021, 124, 142–155. [Google Scholar] [CrossRef]
  4. Anampa, J.; Makower, D.; Sparano, J.A. Progress in Adjuvant Chemotherapy for Breast Cancer: An Overview. BMC Med. 2015, 13, 195. [Google Scholar] [CrossRef]
  5. Torti, F.M.; Bristow, M.M.; Lum, B.L.; Carter, S.K.; Howes, A.E.; Aston, D.A.; Brown, B.W.; Hannigan, J.F.; Meyers, F.J.; Mitchell, E.P. Cardiotoxicity of Epirubicin and Doxorubicin: Assessment by Endomyocardial Biopsy. Cancer Res. 1986, 46, 3722–3727. [Google Scholar]
  6. Wilson, H.E.; Stanton, D.A.; Rellick, S.; Geldenhuys, W.; Pistilli, E.E. Breast Cancer-Associated Skeletal Muscle Mitochondrial Dysfunction and Lipid Accumulation Is Reversed by PPARG. Am. J. Physiol. Cell Physiol. 2021, 320, C577–C590. [Google Scholar] [CrossRef] [PubMed]
  7. Roda, E.; Luca, F.D.; Locatelli, C.A.; Ratto, D.; Di Iorio, C.; Savino, E.; Bottone, M.G.; Rossi, P. From a Medicinal Mushroom Blend a Direct Anticancer Effect on Triple-Negative Breast Cancer: A Preclinical Study on Lung Metastases. Molecules 2020, 25, 5400. [Google Scholar] [CrossRef] [PubMed]
  8. Luca, F.D.; Roda, E.; Ratto, D.; Desiderio, A.; Venuti, M.T.; Ramieri, M.; Bottone, M.G.; Savino, E.; Rossi, P. Fighting Secondary Triple-Negative Breast Cancer in Cerebellum: A Powerful Aid from a Medicinal Mushrooms Blend. Biomed. Pharmacother. 2023, 159, 114262. [Google Scholar] [CrossRef]
  9. Rajarajeswaran, P.; Vishnupriya, R. Exercise in Cancer. Indian J. Med. Paediatr. Oncol. 2009, 30, 61–70. [Google Scholar] [CrossRef]
  10. Frisch, R.E.; Wyshak, G.; Albright, N.L.; Albright, T.E.; Schiff, I.; Jones, K.P.; Witschi, J.; Shiang, E.; Koff, E.; Marguglio, M. Lower Prevalence of Breast Cancer and Cancers of the Reproductive System among Former College Athletes Compared to Non-Athletes. Br. J. Cancer 1985, 52, 885–891. [Google Scholar] [CrossRef]
  11. Orlandella, F.M.; De Stefano, A.E.; Iervolino, P.L.C.; Buono, P.; Soricelli, A.; Salvatore, G. Dissecting the Molecular Pathways Involved in the Effects of Physical Activity on Breast Cancers Cells: A Narrative Review. Life Sci. 2021, 265, 118790. [Google Scholar] [CrossRef]
  12. Schmitz, K.H.; Courneya, K.S.; Matthews, C.; Demark-Wahnefried, W.; Galvão, D.A.; Pinto, B.M.; Irwin, M.L.; Wolin, K.Y.; Segal, R.J.; Lucia, A.; et al. American College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors. Med. Sci. Sports Exerc. 2010, 42, 1409–1426. [Google Scholar] [CrossRef]
  13. Schumann, M.; Freitag, N.; Bloch, W. Advanced Exercise Prescription for Cancer Patients and Its Application in Germany. J. Sci. Sport Exerc. 2020, 2, 201–214. [Google Scholar] [CrossRef]
  14. Thomas, G.A. Using a Network Physiology Approach to Prescribe Exercise for Exercise Oncology. Front. Netw. Physiol. 2022, 2, 877676. [Google Scholar] [CrossRef]
  15. Roeland, E.J.; Ma, J.D.; Nelson, S.H.; Seibert, T.; Heavey, S.; Revta, C.; Gallivan, A.; Baracos, V.E. Weight Loss versus Muscle Loss: Re-Evaluating Inclusion Criteria for Future Cancer Cachexia Interventional Trials. Support. Care Cancer 2017, 25, 365–369. [Google Scholar] [CrossRef]
  16. McMillin, S.L.; Minchew, E.C.; Lowe, D.A.; Spangenburg, E.E. Skeletal Muscle Wasting: The Estrogen Side of Sexual Dimorphism. Am. J. Physiol. Cell Physiol. 2022, 322, C24–C37. [Google Scholar] [CrossRef]
  17. Montero, D.; Madsen, K.; Meinild-Lundby, A.-K.; Edin, F.; Lundby, C. Sexual Dimorphism of Substrate Utilization: Differences in Skeletal Muscle Mitochondrial Volume Density and Function. Exp. Physiol. 2018, 103, 851–859. [Google Scholar] [CrossRef]
  18. Antoun, S.; Borget, I.; Lanoy, E. Impact of Sarcopenia on the Prognosis and Treatment Toxicities in Patients Diagnosed with Cancer. Curr. Opin. Support. Palliat. Care 2013, 7, 383–389. [Google Scholar] [CrossRef]
  19. Fragala, M.S.; Cadore, E.L.; Dorgo, S.; Izquierdo, M.; Kraemer, W.J.; Peterson, M.D.; Ryan, E.D. Resistance Training for Older Adults: Position Statement from the National Strength and Conditioning Association. J. Strength. Cond. Res. 2019, 33, 2019–2052. [Google Scholar] [CrossRef]
  20. Winters-Stone, K.M.; Dobek, J.; Nail, L.; Bennett, J.A.; Leo, M.C.; Naik, A.; Schwartz, A. Strength Training Stops Bone Loss and Builds Muscle in Postmenopausal Breast Cancer Survivors: A Randomized, Controlled Trial. Breast Cancer Res. Treat. 2011, 127, 447–456. [Google Scholar] [CrossRef]
  21. Campbell, K.L.; Winters-Stone, K.; Wiskemann, J.; May, A.M.; Schwartz, A.L.; Courneya, K.S.; Zucker, D.; Matthews, C.; Ligibel, J.; Gerber, L.; et al. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med. Sci. Sports Exerc. 2019, 51, 2375–2390. [Google Scholar] [CrossRef] [PubMed]
  22. Stout, N.L.; Santa Mina, D.; Lyons, K.D.; Robb, K.; Silver, J.K. A Systematic Review of Rehabilitation and Exercise Recommendations in Oncology Guidelines. CA Cancer J. Clin. 2021, 71, 149–175. [Google Scholar] [CrossRef] [PubMed]
  23. Kirkham, A.A.; Bonsignore, A.; Bland, K.A.; Mckenzie, D.C.; Gelmon, K.A.; Van Patten, C.L.; Campbell, K.L. Exercise Prescription and Adherence for Breast Cancer: One Size Does Not FITT All. Med. Sci. Sports Exerc. 2018, 50, 177–186. [Google Scholar] [CrossRef] [PubMed]
  24. Mallard, J.; Hucteau, E.; Hureau, T.J.; Pagano, A.F. Skeletal Muscle Deconditioning in Breast Cancer Patients Undergoing Chemotherapy: Current Knowledge and Insights from Other Cancers. Front. Cell Dev. Biol. 2021, 9, 719643. [Google Scholar] [CrossRef]
  25. Baracos, V.E.; Martin, L.; Korc, M.; Guttridge, D.C.; Fearon, K.C.H. Cancer-Associated Cachexia. Nat. Rev. Dis. Primers 2018, 4, 17105. [Google Scholar] [CrossRef] [PubMed]
  26. Guigni, B.A.; Callahan, D.M.; Tourville, T.W.; Miller, M.S.; Fiske, B.; Voigt, T.; Korwin-Mihavics, B.; Anathy, V.; Dittus, K.; Toth, M.J. Skeletal Muscle Atrophy and Dysfunction in Breast Cancer Patients: Role for Chemotherapy-Derived Oxidant Stress. Am. J. Physiol. Cell Physiol. 2018, 315, C744–C756. [Google Scholar] [CrossRef] [PubMed]
  27. Courneya, K.S.; Segal, R.J.; Mackey, J.R.; Gelmon, K.; Reid, R.D.; Friedenreich, C.M.; Ladha, A.B.; Proulx, C.; Vallance, J.K.H.; Lane, K.; et al. Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial. J. Clin. Oncol. 2007, 25, 4396–4404. [Google Scholar] [CrossRef] [PubMed]
  28. Schmidt, T.; Weisser, B.; Dürkop, J.; Jonat, W.; Van Mackelenbergh, M.; Röcken, C.; Mundhenke, C. Comparing Endurance and Resistance Training with Standard Care during Chemotherapy for Patients with Primary Breast Cancer. Anticancer Res. 2015, 35, 5623–5629. [Google Scholar] [PubMed]
  29. Møller, A.B.; Lønbro, S.; Farup, J.; Voss, T.S.; Rittig, N.; Wang, J.; Højris, I.; Mikkelsen, U.R.; Jessen, N. Molecular and Cellular Adaptations to Exercise Training in Skeletal Muscle from Cancer Patients Treated with Chemotherapy. J. Cancer Res. Clin. Oncol. 2019, 145, 1449–1460. [Google Scholar] [CrossRef]
  30. Wengström, Y.; Bolam, K.A.; Mijwel, S.; Sundberg, C.J.; Backman, M.; Browall, M.; Norrbom, J.; Rundqvist, H. Optitrain: A Randomised Controlled Exercise Trial for Women with Breast Cancer Undergoing Chemotherapy. BMC Cancer 2017, 17, 100. [Google Scholar] [CrossRef]
  31. Padrão, A.I.; Figueira, A.C.C.; Faustino-Rocha, A.I.; Gama, A.; Loureiro, M.M.; Neuparth, M.J.; Moreira-Gonçalves, D.; Vitorino, R.; Amado, F.; Santos, L.L.; et al. Long-Term Exercise Training Prevents Mammary Tumorigenesis-Induced Muscle Wasting in Rats through the Regulation of TWEAK Signalling. Acta Physiol. 2017, 219, 803–813. [Google Scholar] [CrossRef] [PubMed]
  32. Alves de Lima, E.; de Teixeira, A.A.S.; Biondo, L.A.; Diniz, T.A.; Silveira, L.S.; Coletti, D.; Busquets Rius, S.; Rosa Neto, J.C. Exercise Reduces the Resumption of Tumor Growth and Proteolytic Pathways in the Skeletal Muscle of Mice Following Chemotherapy. Cancers 2020, 12, 3466. [Google Scholar] [CrossRef] [PubMed]
  33. Ballarò, R.; Beltrà, M.; De Lucia, S.; Pin, F.; Ranjbar, K.; Hulmi, J.J.; Costelli, P.; Penna, F. Moderate Exercise in Mice Improves Cancer Plus Chemotherapy-Induced Muscle Wasting and Mitochondrial Alterations. FASEB J. 2019, 33, 5482–5494. [Google Scholar] [CrossRef] [PubMed]
  34. Smuder, A.J.; Kavazis, A.N.; Min, K.; Powers, S.K. Exercise Protects against Doxorubicin-Induced Markers of Autophagy Signaling in Skeletal Muscle. J. Appl. Physiol. 2011, 111, 1190–1198. [Google Scholar] [CrossRef] [PubMed]
  35. Bredahl, E.C.; Pfannenstiel, K.B.; Quinn, C.J.; Hayward, R.; Hydock, D.S. Effects of Exercise on Doxorubicin-Induced Skeletal Muscle Dysfunction. Med. Sci. Sports Exerc. 2016, 48, 1468–1473. [Google Scholar] [CrossRef] [PubMed]
  36. Quinn, C.J.; Hydock, D.S. Effects of Endurance Exercise and Doxorubicin on Skeletal Muscle Myogenic Regulatory Factor Expression. Muscles Ligaments Tendons J. 2017, 7, 418–425. [Google Scholar] [CrossRef] [PubMed]
  37. Klassen, O.; Schmidt, M.E.; Ulrich, C.M.; Schneeweiss, A.; Potthoff, K.; Steindorf, K.; Wiskemann, J. Muscle Strength in Breast Cancer Patients Receiving Different Treatment Regimes: Muscle Strength in Breast Cancer Patients. J. Cachexia Sarcopenia Muscle 2017, 8, 305–316. [Google Scholar] [CrossRef]
  38. Winters-Stone, K.M.; Torgrimson-Ojerio, B.; Dieckmann, N.F.; Stoyles, S.; Mitri, Z.; Luoh, S.-W. A Randomized-Controlled Trial Comparing Supervised Aerobic Training to Resistance Training Followed by Unsupervised Exercise on Physical Functioning in Older Breast Cancer Survivors. J. Geriatr. Oncol. 2022, 13, 152–160. [Google Scholar] [CrossRef]
  39. American College of Sports; Medicine American College of Sports; Medicine Position Stand. Progression Models in Resistance Training for Healthy Adults. Med. Sci. Sports Exerc. 2009, 41, 687–708. [Google Scholar] [CrossRef]
  40. Kannus, P. Isokinetic Evaluation of Muscular Performance: Implications for Muscle Testing and Rehabilitation. Int. J. Sports Med. 1994, 15 (Suppl. S1), S11–S18. [Google Scholar] [CrossRef]
  41. McNeely, M.L.; Campbell, K.L.; Rowe, B.H.; Klassen, T.P.; Mackey, J.R.; Courneya, K.S. Effects of Exercise on Breast Cancer Patients and Survivors: A Systematic Review and Meta-Analysis. Can. Med. Assoc. J. 2006, 175, 34–41. [Google Scholar] [CrossRef] [PubMed]
  42. Floyd, A.; Moyer, A. Group versus Individual Exercise Interventions for Women with Breast Cancer: A Meta-Analysis. Health Psychol. Rev. 2010, 4, 22–41. [Google Scholar] [CrossRef] [PubMed]
  43. Winters-Stone, K.M.; Dobek, J.; Bennett, J.A.; Nail, L.M.; Leo, M.C.; Schwartz, A. The Effect of Resistance Training on Muscle Strength and Physical Function in Older, Postmenopausal Breast Cancer Survivors: A Randomized Controlled Trial. J. Cancer Surviv. 2012, 6, 189–199. [Google Scholar] [CrossRef] [PubMed]
  44. Campbell, A.; Mutrie, N.; White, F.; McGuire, F.; Kearney, N. A Pilot Study of a Supervised Group Exercise Programme as a Rehabilitation Treatment for Women with Breast Cancer Receiving Adjuvant Treatment. Eur. J. Oncol. Nurs. 2005, 9, 56–63. [Google Scholar] [CrossRef] [PubMed]
  45. Capozzi, L.C.; McNeely, M.L.; Lau, H.Y.; Reimer, R.A.; Giese-Davis, J.; Fung, T.S.; Culos-Reed, S.N. Patient-Reported Outcomes, Body Composition, and Nutrition Status in Patients with Head and Neck Cancer: Results from an Exploratory Randomized Controlled Exercise Trial. Cancer 2016, 122, 1185–1200. [Google Scholar] [CrossRef] [PubMed]
  46. Moley, J.F.; Aamodt, R.; Rumble, W.; Kaye, W.; Norton, J.A. Body Cell Mass in Cancer-Bearing and Anorexic Patients. JPEN J. Parenter. Enteral Nutr. 1987, 11, 219–222. [Google Scholar] [CrossRef]
  47. Friesen, D.E.; Baracos, V.E.; Tuszynski, J.A. Modeling the Energetic Cost of Cancer as a Result of Altered Energy Metabolism: Implications for Cachexia. Theor. Biol. Med. Model. 2015, 12, 17. [Google Scholar] [CrossRef] [PubMed]
  48. Mallard, J.; Hucteau, E.; Schott, R.; Trensz, P.; Pflumio, C.; Kalish-Weindling, M.; Favret, F.; Pivot, X.; Hureau, T.J.; Pagano, A.F. Early Skeletal Muscle Deconditioning and Reduced Exercise Capacity during (Neo)Adjuvant Chemotherapy in Patients with Breast Cancer. Cancer 2023, 129, 215–225. [Google Scholar] [CrossRef]
  49. Cao, D.; Wu, G.; Zhang, B.; Quan, Y.; Wei, J.; Jin, H.; Jiang, Y.; Yang, Z. Resting Energy Expenditure and Body Composition in Patients with Newly Detected Cancer. Clin. Nutr. 2010, 29, 72–77. [Google Scholar] [CrossRef]
  50. Soom, T.V.; Tjalma, W.; Daele, U.V.; Gebruers, N.; Breda, E.V. Resting Energy Expenditure, Body Composition, and Metabolic Alterations in Breast Cancer Survivors vs. Healthy Controls: A Cross-Sectional Study. BMC Women’s Health 2024, 24, 117. [Google Scholar] [CrossRef]
  51. Lovejoy, J.C.; Champagne, C.M.; de Jonge, L.; Xie, H.; Smith, S.R. Increased Visceral Fat and Decreased Energy Expenditure during the Menopausal Transition. Int. J. Obes. 2008, 32, 949–958. [Google Scholar] [CrossRef] [PubMed]
  52. Prado, C.M.M.; Baracos, V.E.; McCargar, L.J.; Mourtzakis, M.; Mulder, K.E.; Reiman, T.; Butts, C.A.; Scarfe, A.G.; Sawyer, M.B. Body Composition as an Independent Determinant of 5-Fluorouracil-Based Chemotherapy Toxicity. Clin. Cancer Res. 2007, 13, 3264–3268. [Google Scholar] [CrossRef] [PubMed]
  53. Campbell, K.L.; Lane, K.; Martin, A.D.; Gelmon, K.A.; McKenzie, D.C. Resting Energy Expenditure and Body Mass Changes in Women during Adjuvant Chemotherapy for Breast Cancer. Cancer Nurs. 2007, 30, 95–100. [Google Scholar] [CrossRef] [PubMed]
  54. Durkin, K.; Heetun, A.; Ewings, S.; Munday, R.; Wootton, S.A.; Turner, L.; Copson, E.R.; Cutress, R.I. Body Composition and Chemotherapy Toxicity in Women with Early Breast Cancer (CANDO-3): Protocol for an Observational Cohort Study. BMJ Open 2022, 12, e054412. [Google Scholar] [CrossRef] [PubMed]
  55. Wilkinson, S.B.; Phillips, S.M.; Atherton, P.J.; Patel, R.; Yarasheski, K.E.; Tarnopolsky, M.A.; Rennie, M.J. Differential Effects of Resistance and Endurance Exercise in the Fed State on Signalling Molecule Phosphorylation and Protein Synthesis in Human Muscle. J. Physiol. 2008, 586, 3701–3717. [Google Scholar] [CrossRef]
  56. Martin, A.; Freyssenet, D. Phenotypic Features of Cancer Cachexia-related Loss of Skeletal Muscle Mass and Function: Lessons from Human and Animal Studies. J. Cachexia Sarcopenia Muscle 2021, 12, 252–273. [Google Scholar] [CrossRef] [PubMed]
  57. Lim, S.; Dunlap, K.R.; Rosa-Caldwell, M.E.; Haynie, W.S.; Jansen, L.T.; Washington, T.A.; Greene, N.P. Comparative Plasma Proteomics in Muscle Atrophy during Cancer-Cachexia and Disuse: The Search for Atrokines. Physiol. Rep. 2020, 8, e14608. [Google Scholar] [CrossRef]
  58. Hain, B.A.; Xu, H.; Wilcox, J.R.; Mutua, D.; Waning, D.L. Chemotherapy-Induced Loss of Bone and Muscle Mass in a Mouse Model of Breast Cancer Bone Metastases and Cachexia. JCSM Rapid Commun. 2019, 2, 1–12. [Google Scholar] [CrossRef]
  59. Min, K.; Kwon, O.-S.; Smuder, A.J.; Wiggs, M.P.; Sollanek, K.J.; Christou, D.D.; Yoo, J.-K.; Hwang, M.-H.; Szeto, H.H.; Kavazis, A.N.; et al. Increased Mitochondrial Emission of Reactive Oxygen Species and Calpain Activation Are Required for Doxorubicin-Induced Cardiac and Skeletal Muscle Myopathy. J. Physiol. 2015, 593, 2017–2036. [Google Scholar] [CrossRef]
  60. Bonetto, A.; Rupert, J.E.; Barreto, R.; Zimmers, T.A. The Colon-26 Carcinoma Tumor-Bearing Mouse as a Model for the Study of Cancer Cachexia. JoVE J. Vis. Exp. 2016, 117, e54893. [Google Scholar] [CrossRef]
  61. Kwon, I. Protective Effects of Endurance Exercise on Skeletal Muscle Remodeling against Doxorubicin-Induced Myotoxicity in Mice. Phys. Act. Nutr. 2020, 24, 11–21. [Google Scholar] [CrossRef] [PubMed]
  62. Tarpey, M.D.; Amorese, A.J.; Balestrieri, N.P.; Fisher-Wellman, K.H.; Spangenburg, E.E. Doxorubicin Causes Lesions in the Electron Transport System of Skeletal Muscle Mitochondria That Are Associated with a Loss of Contractile Function. J. Biol. Chem. 2019, 294, 19709–19722. [Google Scholar] [CrossRef] [PubMed]
  63. Christensen, J.F.; Andersen, J.L.; Adamsen, L.; Lindegaard, B.; Mackey, A.L.; Nielsen, R.H.; Rørth, M.; Daugaard, G. Progressive Resistance Training and Cancer Testis (PROTRACT)—Efficacy of Resistance Training on Muscle Function, Morphology and Inflammatory Profile in Testicular Cancer Patients Undergoing Chemotherapy: Design of a Randomized Controlled Trial. BMC Cancer 2011, 11, 326. [Google Scholar] [CrossRef] [PubMed]
  64. Collao, N.; Sanders, O.; Caminiti, T.; Messeiller, L.; De Lisio, M. Resistance and Endurance Exercise Training Improves Muscle Mass and the Inflammatory/Fibrotic Transcriptome in a Rhabdomyosarcoma Model. J. Cachexia Sarcopenia Muscle 2023, 14, 781–793. [Google Scholar] [CrossRef]
  65. White, J.P.; Puppa, M.J.; Sato, S.; Gao, S.; Price, R.L.; Baynes, J.W.; Kostek, M.C.; Matesic, L.E.; Carson, J.A. IL-6 Regulation on Skeletal Muscle Mitochondrial Remodeling during Cancer Cachexia in the ApcMin/+ Mouse. Skelet. Muscle 2012, 2, 14. [Google Scholar] [CrossRef]
  66. Pigna, E.; Berardi, E.; Aulino, P.; Rizzuto, E.; Zampieri, S.; Carraro, U.; Kern, H.; Merigliano, S.; Gruppo, M.; Mericskay, M.; et al. Aerobic Exercise and Pharmacological Treatments Counteract Cachexia by Modulating Autophagy in Colon Cancer. Sci. Rep. 2016, 6, 26991. [Google Scholar] [CrossRef] [PubMed]
  67. Pin, F.; Busquets, S.; Toledo, M.; Camperi, A.; Lopez-Soriano, F.J.; Costelli, P.; Argilés, J.M.; Penna, F. Combination of Exercise Training and Erythropoietin Prevents Cancer-Induced Muscle Alterations. Oncotarget 2015, 6, 43202–43215. [Google Scholar] [CrossRef]
  68. LIU, M.-H.; ZHANG, Y.; HE, J.; TAN, T.-P.; WU, S.-J.; FU, H.-Y.; CHEN, Y.-D.; LIU, J.; LE, Q.-F.; HU, H.-J.; et al. Upregulation of Peroxiredoxin III in Doxorubicin-Induced Cytotoxicity and the FoxO3a-Dependent Expression in H9c2 Cardiac Cells. Exp. Ther. Med. 2015, 10, 1515–1520. [Google Scholar] [CrossRef]
  69. Constantinou, C.; Fontes de Oliveira, C.C.; Mintzopoulos, D.; Busquets, S.; He, J.; Kesarwani, M.; Mindrinos, M.; Rahme, L.G.; Argilés, J.M.; Tzika, A.A. Nuclear Magnetic Resonance in Conjunction with Functional Genomics Suggests Mitochondrial Dysfunction in a Murine Model of Cancer Cachexia. Int. J. Mol. Med. 2011, 27, 15–24. [Google Scholar] [CrossRef]
  70. McLean, J.B.; Moylan, J.S.; Andrade, F.H. Mitochondria Dysfunction in Lung Cancer-Induced Muscle Wasting in C2C12 Myotubes. Front. Physiol. 2014, 5, 503. [Google Scholar] [CrossRef]
  71. Ying, W.; Garnier, P.; Swanson, R.A. NAD+ Repletion Prevents PARP-1-Induced Glycolytic Blockade and Cell Death in Cultured Mouse Astrocytes. Biochem. Biophys. Res. Commun. 2003, 308, 809–813. [Google Scholar] [CrossRef] [PubMed]
  72. Gilliam, L.A.A.; Moylan, J.S.; Patterson, E.W.; Smith, J.D.; Wilson, A.S.; Rabbani, Z.; Reid, M.B. Doxorubicin Acts via Mitochondrial ROS to Stimulate Catabolism in C2C12 Myotubes. Am. J. Physiol. Cell Physiol. 2012, 302, C195–C202. [Google Scholar] [CrossRef] [PubMed]
  73. Sorensen, J.C.; Cheregi, B.D.; Timpani, C.A.; Nurgali, K.; Hayes, A.; Rybalka, E. Mitochondria: Inadvertent Targets in Chemotherapy-Induced Skeletal Muscle Toxicity and Wasting? Cancer Chemother. Pharmacol. 2016, 78, 673–683. [Google Scholar] [CrossRef] [PubMed]
  74. Doerr, V.; Montalvo, R.N.; Kwon, O.S.; Talbert, E.E.; Hain, B.A.; Houston, F.E.; Smuder, A.J. Prevention of Doxorubicin-Induced Autophagy Attenuates Oxidative Stress and Skeletal Muscle Dysfunction. Antioxidants 2020, 9, 263. [Google Scholar] [CrossRef] [PubMed]
  75. Gorini, S.; De Angelis, A.; Berrino, L.; Malara, N.; Rosano, G.; Ferraro, E. Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib. Oxidative Med. Cell. Longev. 2018, 2018, e7582730. [Google Scholar] [CrossRef] [PubMed]
  76. Gilliam, L.A.A.; Ferreira, L.F.; Bruton, J.D.; Moylan, J.S.; Westerblad, H.; St Clair, D.K.; Reid, M.B. Doxorubicin Acts through Tumor Necrosis Factor Receptor Subtype 1 to Cause Dysfunction of Murine Skeletal Muscle. J. Appl. Physiol. 2009, 107, 1935–1942. [Google Scholar] [CrossRef] [PubMed]
  77. Glass, D.J. PI3 Kinase Regulation of Skeletal Muscle Hypertrophy and Atrophy. In Phosphoinositide 3-kinase in Health and Disease: Volume 1; Rommel, C., Vanhaesebroeck, B., Vogt, P.K., Eds.; Current Topics in Microbiology and Immunology; Springer: Berlin, Heidelberg, Germany, 2011; pp. 267–278. ISBN 978-3-642-13663-4. [Google Scholar]
  78. Merino, H.; Singla, D.K. Secreted Frizzled-Related Protein-2 Inhibits Doxorubicin-Induced Apoptosis Mediated through the Akt-mTOR Pathway in Soleus Muscle. Oxidative Med. Cell. Longev. 2018, 2018, e6043064. [Google Scholar] [CrossRef] [PubMed]
  79. Ismaeel, A.; Holmes, M.; Papoutsi, E.; Panton, L.; Koutakis, P. Resistance Training, Antioxidant Status, and Antioxidant Supplementation. Int. J. Sport Nutr. Exerc. Metab. 2019, 29, 539–547. [Google Scholar] [CrossRef] [PubMed]
  80. Ji, L.L.; Gomez-Cabrera, M.-C.; Vina, J. Exercise and Hormesis: Activation of Cellular Antioxidant Signaling Pathway. Ann. N. Y. Acad. Sci. 2006, 1067, 425–435. [Google Scholar] [CrossRef]
  81. Silveira, L.R.; Pilegaard, H.; Kusuhara, K.; Curi, R.; Hellsten, Y. The Contraction Induced Increase in Gene Expression of Peroxisome Proliferator-Activated Receptor (PPAR)-Gamma Coactivator 1alpha (PGC-1alpha), Mitochondrial Uncoupling Protein 3 (UCP3) and Hexokinase II (HKII) in Primary Rat Skeletal Muscle Cells Is Dependent on Reactive Oxygen Species. Biochim. Biophys. Acta 2006, 1763, 969–976. [Google Scholar] [CrossRef]
  82. Pettersen, K.; Andersen, S.; Degen, S.; Tadini, V.; Grosjean, J.; Hatakeyama, S.; Tesfahun, A.N.; Moestue, S.; Kim, J.; Nonstad, U.; et al. Cancer Cachexia Associates with a Systemic Autophagy-Inducing Activity Mimicked by Cancer Cell-Derived IL-6 Trans-Signaling. Sci. Rep. 2017, 7, 2046. [Google Scholar] [CrossRef] [PubMed]
  83. Zhao, J.; Brault, J.J.; Schild, A.; Cao, P.; Sandri, M.; Schiaffino, S.; Lecker, S.H.; Goldberg, A.L. FoxO3 Coordinately Activates Protein Degradation by the Autophagic/Lysosomal and Proteasomal Pathways in Atrophying Muscle Cells. Cell Metab. 2007, 6, 472–483. [Google Scholar] [CrossRef] [PubMed]
  84. Jain, K.; Paranandi, K.S.; Sridharan, S.; Basu, A. Autophagy in Breast Cancer and Its Implications for Therapy. Am. J. Cancer Res. 2013, 3, 251–265. [Google Scholar]
  85. Rogov, V.; Dötsch, V.; Johansen, T.; Kirkin, V. Interactions between Autophagy Receptors and Ubiquitin-like Proteins Form the Molecular Basis for Selective Autophagy. Mol. Cell 2014, 53, 167–178. [Google Scholar] [CrossRef] [PubMed]
  86. Sandri, M. Autophagy in Health and Disease. 3. Involvement of Autophagy in Muscle Atrophy. Am. J. Physiol. Cell Physiol. 2010, 298, C1291–C1297. [Google Scholar] [CrossRef]
  87. Wang, X.; Blagden, C.; Fan, J.; Nowak, S.J.; Taniuchi, I.; Littman, D.R.; Burden, S.J. Runx1 Prevents Wasting, Myofibrillar Disorganization, and Autophagy of Skeletal Muscle. Genes Dev. 2005, 19, 1715–1722. [Google Scholar] [CrossRef] [PubMed]
  88. de Testa, M.T.J.; Cella, P.S.; Marinello, P.C.; Frajacomo, F.T.T.; de S. Padilha, C.; Perandini, P.C.; Moura, F.A.; Duarte, J.A.; Cecchini, R.; Guarnier, F.A.; et al. Resistance Training Attenuates Activation of STAT3 and Muscle Atrophy in Tumor-Bearing Mice. Front. Oncol. 2022, 12, 880787. [Google Scholar] [CrossRef] [PubMed]
  89. Kleckner, I.R.; Kamen, C.; Cole, C.; Fung, C.; Heckler, C.E.; Guido, J.J.; Culakova, E.; Onitilo, A.A.; Conlin, A.; Kuebler, J.P.; et al. Effects of Exercise on Inflammation in Patients Receiving Chemotherapy: A Nationwide NCORP Randomized Clinical Trial. Support. Care Cancer 2019, 27, 4615–4625. [Google Scholar] [CrossRef]
  90. Kosmidou, I.; Vassilakopoulos, T.; Xagorari, A.; Zakynthinos, S.; Papapetropoulos, A.; Roussos, C. Production of Interleukin-6 by Skeletal Myotubes. Am. J. Respir. Cell Mol. Biol. 2002, 26, 587–593. [Google Scholar] [CrossRef]
  91. Schauer, T.; Mazzoni, A.-S.; Henriksson, A.; Demmelmaier, I.; Berntsen, S.; Raastad, T.; Nordin, K.; Pedersen, B.K.; Christensen, J.F. Exercise Intensity and Markers of Inflammation during and after (Neo-) Adjuvant Cancer Treatment. Endocr. Relat. Cancer 2021, 28, 191–201. [Google Scholar] [CrossRef]
  92. Serra, M.C.; Ryan, A.S.; Ortmeyer, H.K.; Addison, O.; Goldberg, A.P. Resistance Training Reduces Inflammation and Fatigue and Improves Physical Function in Older Breast Cancer Survivors. Menopause 2018, 25, 211. [Google Scholar] [CrossRef] [PubMed]
  93. Phillips, M.D.; Patrizi, R.M.; Cheek, D.J.; Wooten, J.S.; Barbee, J.J.; Mitchell, J.B. Resistance Training Reduces Subclinical Inflammation in Obese, Postmenopausal Women. Med. Sci. Sports Exerc. 2012, 44, 2099. [Google Scholar] [CrossRef] [PubMed]
  94. Henriques, F.; Lopes, M.A.; Franco, F.O.; Knobl, P.; Santos, K.B.; Bueno, L.L.; Correa, V.A.; Bedard, A.H.; Guilherme, A.; Birbrair, A.; et al. Toll-Like Receptor-4 Disruption Suppresses Adipose Tissue Remodeling and Increases Survival in Cancer Cachexia Syndrome. Sci. Rep. 2018, 8, 18024. [Google Scholar] [CrossRef] [PubMed]
  95. Yoshikawa, T.; Noguchi, Y.; Matsumoto, A. Effects of Tumor Removal and Body Weight Loss on Insulin Resistance in Patients with Cancer. Surgery 1994, 116, 62–66. [Google Scholar] [PubMed]
  96. Noguchi, Y.; Yoshikawa, T.; Marat, D.; Doi, C.; Makino, T.; Fukuzawa, K.; Tsuburaya, A.; Satoh, S.; Ito, T.; Mitsuse, S. Insulin Resistance in Cancer Patients Is Associated with Enhanced Tumor Necrosis Factor-α Expression in Skeletal Muscle. Biochem. Biophys. Res. Commun. 1998, 253, 887–892. [Google Scholar] [CrossRef] [PubMed]
  97. Hojman, P.; Fjelbye, J.; Zerahn, B.; Christensen, J.F.; Dethlefsen, C.; Lonkvist, C.K.; Brandt, C.; Gissel, H.; Pedersen, B.K.; Gehl, J. Voluntary Exercise Prevents Cisplatin-Induced Muscle Wasting during Chemotherapy in Mice. PLoS ONE 2014, 9, e109030. [Google Scholar] [CrossRef] [PubMed]
  98. Earnest, C.P.; Johannsen, N.M.; Swift, D.L.; Gillison, F.B.; Mikus, C.R.; Lucia, A.; Kramer, K.; Lavie, C.J.; Church, T.S. Aerobic and Strength Training in Concomitant Metabolic Syndrome and Type 2 Diabetes. Med. Sci. Sports Exerc. 2014, 46, 1293–1301. [Google Scholar] [CrossRef] [PubMed]
  99. Cuff, D.J.; Meneilly, G.S.; Martin, A.; Ignaszewski, A.; Tildesley, H.D.; Frohlich, J.J. Effective Exercise Modality to Reduce Insulin Resistance in Women with Type 2 Diabetes. Diabetes Care 2003, 26, 2977–2982. [Google Scholar] [CrossRef] [PubMed]
  100. Sandri, M.; Lin, J.; Handschin, C.; Yang, W.; Arany, Z.P.; Lecker, S.H.; Goldberg, A.L.; Spiegelman, B.M. PGC-1α Protects Skeletal Muscle from Atrophy by Suppressing FoxO3 Action and Atrophy-Specific Gene Transcription. Proc. Natl. Acad. Sci. USA 2006, 103, 16260–16265. [Google Scholar] [CrossRef]
  101. Arany, Z.; Lebrasseur, N.; Morris, C.; Smith, E.; Yang, W.; Ma, Y.; Chin, S.; Spiegelman, B.M. The Transcriptional Coactivator PGC-1β Drives the Formation of Oxidative Type IIX Fibers in Skeletal Muscle. Cell Metab. 2007, 5, 35–46. [Google Scholar] [CrossRef]
  102. Stitt, T.N.; Drujan, D.; Clarke, B.A.; Panaro, F.; Timofeyva, Y.; Kline, W.O.; Gonzalez, M.; Yancopoulos, G.D.; Glass, D.J. The IGF-1/PI3K/Akt Pathway Prevents Expression of Muscle Atrophy-Induced Ubiquitin Ligases by Inhibiting FOXO Transcription Factors. Mol. Cell 2004, 14, 395–403. [Google Scholar] [CrossRef] [PubMed]
  103. Padilha, C.S.; Borges, F.H.; Costa Mendes da Silva, L.E.; Frajacomo, F.T.T.; Jordao, A.A.; Duarte, J.A.; Cecchini, R.; Guarnier, F.A.; Deminice, R. Resistance Exercise Attenuates Skeletal Muscle Oxidative Stress, Systemic Pro-Inflammatory State, and Cachexia in Walker-256 Tumor-Bearing Rats. Appl. Physiol. Nutr. Metab. 2017, 42, 916–923. [Google Scholar] [CrossRef] [PubMed]
  104. McFarlane, C.; Plummer, E.; Thomas, M.; Hennebry, A.; Ashby, M.; Ling, N.; Smith, H.; Sharma, M.; Kambadur, R. Myostatin Induces Cachexia by Activating the Ubiquitin Proteolytic System through an NF-κB-Independent, FoxO1-Dependent Mechanism. J. Cell. Physiol. 2006, 209, 501–514. [Google Scholar] [CrossRef] [PubMed]
  105. Phillips, S.M.; Tipton, K.D.; Aarsland, A.; Wolf, S.E.; Wolfe, R.R. Mixed Muscle Protein Synthesis and Breakdown after Resistance Exercise in Humans. Am. J. Physiol. Endocrinol. Metab. 1997, 273, E99–E107. [Google Scholar] [CrossRef]
  106. Adams, G.R. Role of Insulin-like Growth Factor-I in the Regulation of Skeletal Muscle Adaptation to Increased Loading. Exerc. Sport Sci. Rev. 1998, 26, 31–60. [Google Scholar] [CrossRef]
  107. Basualto-Alarcón, C.; Jorquera, G.; Altamirano, F.; Jaimovich, E.; Estrada, M. Testosterone Signals through mTOR and Androgen Receptor to Induce Muscle Hypertrophy. Med. Sci. Sports Exerc. 2013, 45, 1712–1720. [Google Scholar] [CrossRef]
  108. Alexander, S.E.; Abbott, G.; Aisbett, B.; Wadley, G.D.; Hnatiuk, J.A.; Lamon, S. Total Testosterone Is Not Associated with Lean Mass or Handgrip Strength in Pre-Menopausal Females. Sci. Rep. 2021, 11, 10226. [Google Scholar] [CrossRef] [PubMed]
  109. Phillips, S.K.; Rook, K.M.; Siddle, N.C.; Bruce, S.A.; Woledge, R.C. Muscle Weakness in Women Occurs at an Earlier Age than in Men, but Strength Is Preserved by Hormone Replacement Therapy. Clin. Sci. 1993, 84, 95–98. [Google Scholar] [CrossRef]
  110. Smith, G.I.; Yoshino, J.; Reeds, D.N.; Bradley, D.; Burrows, R.E.; Heisey, H.D.; Moseley, A.C.; Mittendorfer, B. Testosterone and Progesterone, but Not Estradiol, Stimulate Muscle Protein Synthesis in Postmenopausal Women. J. Clin. Endocrinol. Metab. 2014, 99, 256–265. [Google Scholar] [CrossRef]
  111. Collins, B.C.; Arpke, R.W.; Larson, A.A.; Baumann, C.W.; Xie, N.; Cabelka, C.A.; Nash, N.L.; Juppi, H.-K.; Laakkonen, E.K.; Sipilä, S.; et al. Estrogen Regulates the Satellite Cell Compartment in Females. Cell Rep. 2019, 28, 368–381. [Google Scholar] [CrossRef]
  112. de Jonge, X.A.K.J.; Boot, C.R.L.; Thom, J.M.; Ruell, P.A.; Thompson, M.W. The Influence of Menstrual Cycle Phase on Skeletal Muscle Contractile Characteristics in Humans. J. Physiol. 2001, 530, 161–166. [Google Scholar] [CrossRef] [PubMed]
  113. Sung, E.; Han, A.; Hinrichs, T.; Vorgerd, M.; Manchado, C.; Platen, P. Effects of Follicular versus Luteal Phase-Based Strength Training in Young Women. Springerplus 2014, 3, 668. [Google Scholar] [CrossRef] [PubMed]
  114. Ruzić, L.; Matković, B.R.; Leko, G. Antiandrogens in Hormonal Contraception Limit Muscle Strength Gain in Strength Training: Comparison Study. Croat. Med. J. 2003, 44, 65–68. [Google Scholar] [PubMed]
Ijms 25 07533 g001
Figure 1. Bibliometric network analysis of common terms implicated in cancer, chemotherapy, and exercise. Node size is associated with the frequency of the term and the edges signalize co-occurring terms. Different colored lines represent clusters of associated terms. The co-occurrence network visualization map was created using VOSviewer (version 1.6.20).
Figure 1. Bibliometric network analysis of common terms implicated in cancer, chemotherapy, and exercise. Node size is associated with the frequency of the term and the edges signalize co-occurring terms. Different colored lines represent clusters of associated terms. The co-occurrence network visualization map was created using VOSviewer (version 1.6.20).
Ijms 25 07533 g001
Ijms 25 07533 g002
Figure 2. Overview of the key molecular mechanisms involved in Breast Cancer (BC) and chemotherapy-induced muscle wasting, and the impact of different exercise types on them. The BC effect is represented in brown, chemotherapy in blue, aerobic exercise in green, and resistance exercise in purple. Figure was created with BioRender.com.
Figure 2. Overview of the key molecular mechanisms involved in Breast Cancer (BC) and chemotherapy-induced muscle wasting, and the impact of different exercise types on them. The BC effect is represented in brown, chemotherapy in blue, aerobic exercise in green, and resistance exercise in purple. Figure was created with BioRender.com.
Ijms 25 07533 g002
Table 1. Overview of exercise protocols employed in preclinical models of cancer and/or chemotherapy and in clinical studies involving BC patients and reported outcomes.
Table 1. Overview of exercise protocols employed in preclinical models of cancer and/or chemotherapy and in clinical studies involving BC patients and reported outcomes.
ArticleRandomizationExerciseMuscleCancer StageChemotherapyData CollectedOutcomes
Pre-Clinical Studies
Padrão
et al. [31]		Female Sprague-Dawley rats injected with N-Methyl-N-nitrosourea (MNU; 50 mg/kg) at 50 days of age and divided into 2 groups: MNU + SED; MNU + EXStarted 2 days after tumor induction and performed for 35 weeks on a treadmill (20 m/min; 60 min/day; 5 days/week).GastrocnemiusMammary lesions (induced by MNU (50 mg/kg)with 100% incidence No treatment
  • BW and muscle mass
  • morphometry (CSA)
  • serum inflammation and metabolic markers
  • muscle inflammation and metabolic remodeling
  • ↑ CSA after EXER;
  • ↓ serum TWEAK after EXER;
  • ↑ muscle ATP synthase beta/GAPDH, PGC1α, p-Akt/total Akt, 4E-BP1 after EXER;
  • ↓ muscle NF-kB signaling
Alves de Lima et al. [32]C57 BL/6 mice were subcutaneously implanted with Lewis lung carcinoma cells (8–10 wks old) divided into 3 groups: LLC; LLC + DOX; LLC + DOX + EXERStarted 1 wk after tumor inoculation and performed for 2 wk (21 d) or 3 wk (28 d). Aerobic: 5 times/wk, 40–60 min, on treadmill at 60% oxygen consumptionGastrocnemiusSyngeneic model but not with BCDoxorubicin 2 times/wk (cumulative dose 10 mg/kg)
  • BW and composition;
  • Serum parameters (glycemia; lactate; TG; total cholesterol);
  • glucose and insulin test;
  • cytokine expression;
  • biochemical markers of metabolic pathways.
  • ↑ Muscle mass after EXER;
  • EXER: = Serum parameters;
  • EXER: = glucose tolerance and insulin sensitivity;
  • EXER (28 d): = Fbxo32, Trim63 and myostatin expression;
  • EXER (21 d): ↑ FoxO1; EXER (28 d): = FoxO1 and FoxO3;
  • EXER (21 d): ↓ NFkB and ↓ proteolytic activity;
  • EXER: = TLR-4.
Ballarò
et al. [33]		Female and male BALB/c mice (6 wks old) divided in 4 groups: Control (n = 7), C26 (n = 6), C26 OXFU (n = 8) and C26 OXFU ex (n = 8)
C26 mice were subcutaneously implanted with Colon 26 carcinoma cells		Combined: 5 times/wk for 28 d in custom motorized wheel.
Started 5 d before tumor injection at 5 m/min for 15 min, and ↑ until 11 m/min for 45 min.		Gastrocnemius;
Tibialis anterior		Syngeneic model but not with BCOxaliplatin (6 mg/kg) followed (2 h later) by 5-fluorouracil (50 mg/kg), weekly (for 28 d) starting 7 d after tumor injection.
  • BW;
  • flow cytometry;
  • hematocrit;
  • MS.
  • Muscle protein synthesis (surface sensing of translation method);
  • biochemical assay.
  • C26 ex and C26 OXFU ex: counteract MW, by ↑ MS and mass;
  • =hematocrit between groups;
  • =IL-6 between groups;
  • C26 OXFU ex: =STAT3, ↓ Fbxo32 and Trim63 (Gastrocnemius);
  • C26 OXFU ex: ↓ Beclin-1, LC3B and p62 (Gastrocnemius);
  • C26 OXFU ex: ↑ PGC-1α, Cyt-c and SDH (Gastrocnemius);
  • C26 OXFU ex: ↑ Mfn2, whereas =Fis1 and Mfn1 (Gastrocnemius).
Smuder
et al. [34]		23 male adult (6 month old) Sprague-Dawley rats, divided by 4 groups
SED (n = 7); EXETR (n = 6); SEDDOX (n = 5); EXDOX (n = 6)		Aerobic: Treadmill running 5 times/wk (10, 20, 30, 40, 50 min/d on days 1–5). After 2 d rest, performed 60 min/day at 30 m/min (70% oxygen consumption) for more 5 d.SoleusNo cancerDoxorubicin (20 mg/kg), administrated 24 h before sacrifice
  • Histological analysis (H&E, apoptosis);
  • biochemical assay.
  • EXEDOX: ↓ muscle fiber damage;
  • EXEDOX: ↓ Beclin-1, LC3 and ATG12;
  • EXEDOX: ↓ cathepsins.
Bredahl
et al. [35]		60 Sprague-Dawley rats, were divided in 4 groups (RT (n = 20); TM (n = 20); SED (n = 20)). After the exercise protocol were divided in 6 groups of 10 rats (RT + SAL;TM + SAL;SED + SAL;RT + DOX; TM + DOX; SED + DOX)A total of 10 wks. RT: Jump to reach an elevated food and water container, with ↑height during the wk until reaching 8 inches by wk 8. TM: Progressive treadmill training until 60 min, 30 m/min and 18°, representing 65–75% of oxygen consumption.Soleus;
EDL		No cancerA single doxorubicin administration (15 mg/Kg) after the 10 wk exercise program
  • BW and composition;
  • MF, MS (ex vivo skeletal muscle function).
  • TM + DOX: ↓ BW and ↓ EDL mass;
  • RT + DOX: = BW and ↑ EDL mass;
  • TM + DOX: = MS (Soleus and EDL);
  • RT + DOX: ↑ MS (Soleus);
  • RT + SAL and TM + SAL: ↓ MF (Soleus).
Quinn
et al. [36]		47 male Sprague-Dawley rats (10 wk old) divided in 2 groups: SED (n = 20); EXER (n = 27), after 2 wks they were separated into 4 groups: SED + SAL (n = 10); SED + DOX (n = 10); EXER + SAL (n = 13); EXER + DOX (n = 14)Aerobic: Progressive treadmill protocol, starting at 30 m/min for 10 min by wk 1, and ↑ until 60 min by wk 2.Soleus;
EDL;
DIA		No cancerA single doxorubicin administration (15 mg/Kg) 24 h after the last exercise session
  • BW and composition;
  • Biochemical assays.
  • EXER groups: = Soleus mass;
  • EXER + DOX: ↑ EDL mass than SED + DOX;
  • EXER + DOX: ↑ Myf5 and MyoD (Soleus and DIA) and ↑ Myf4 (Soleus).
Clinical Studies
Courneya et al. [27]242 women (49 ± 30 years old), only 219 reported the studied outcomes with
80 patients in each group (AET; RET; UC)		Started 1 wk before chemo. and ended 3 wk after last administration (17 wk) AET: at 60% VO2max* (up 10% every 6 wk until 80%) during 15 min (up 5 min every 3 wk until 45 min) RET: 2 sets of 8–12 reps of 9 exe. (60 or 70% the maximal strength), if 12 reps were performed load ↑ 10%Not availableBreast Cancer in stage I to IIIATaxanes or non-taxanes
  • BW and composition;
  • QoL and fatigue;
  • RDI;
  • MS (by RM);
  • VO2peak, mL/kg/min.
  • QoL = between exercise types;
  • RET: ↑ RDI;
  • AET: ↑ fitness healthy;
  • RET: ↑ MS.
Klassen
et al. [37]		281 women with (57.1 ± 6.1 years old), divided into 5 groups (No CT (n = 105); Started CT (n = 91); Post neo-adj. CT (n = 31); Post adj. CT (n = 28); Healthy (n = 26))Resistance: A total of 12 wk, 2 times/wk. For 60 min, 8 exe. with 1–3 sets, with weight to 8–12 reps (60–80% RM*). 1 min of rest between sets and if 12 reps were performed, the weigh ↑ 5%. Not availableBreast cancer in stage 0 to III after lumpectomy or mastectomyTaxanes and/or Anthracyclines and/or Herceptin
  • QoL and fatigue;
  • MF (muscular fatigue index*);
  • MS (isokinetic and isometric tests).
  • Resistance exercise during CT: ↑ RDI;
  • in post neo-adj. CT: ↑ MF.
Wengström et al. [30]240 women (18–70 years old) divided into 3 groups (AET (n = 80); CT (n = 80); UC (n = 80))60 min, 2 times/wk, 16 wk, with 5 min warm-up in aerobic machine at 10–12 RPE* and 10 min cool-down with scratching exercises. AET: 20 min at 13–15 RPE, followed by 3 × 3 min bouts at 16–18 RPE interspersed with ~1 min of passive or active recovery. CT: 8 exe., 2 sets of 10–12 reps at 70% RM and ↑ to 80% if 12 reps were performed, and 3 × 3 min bouts of AET.Vastus lateralisBreast cancer in stage I to IIIa undergoing chemotherapyTaxanes or Anthracyclines
  • QoL and fatigue;
  • MS (hydraulic hand dynamometer, isometric mid-thigh pull);
  • secondary outcomes (contractile function; systemic inflammation; muscle fiber area; mitochondrial density; expression of genes for muscle adaptation).
  • AET ↓ cancer-related outcomes;
  • in 1-year follow-up, an improvement in MS was still shown. In the 2-year follow-up, a significant maintaining of MS only in the CT group was shown;
  • secondary outcomes not reported.
Schmidt
et al. [28]		67 women (18–70 years old) divided into 3 groups (RT (n = 21); ET (n = 20); SC (n = 26))2 times/wk, 60 min, 12 wk.
ET: 10 min warm-up, followed by 25–30 min exercising on at 11–14 RPE, and 10 min cool-down.
RT: 10 exe. at 1 RM to complete 20 reps.		Not availableBreast cancer with moderate- or high-risk Adj. chemotherapy
  • QoL and fatigue;
  • MS (isometric muscular capacity with M3 Diagnos);
  • endurance stress test on muscles.
  • RT: ↑ RDI;
  • RT: ↑ fatigue and QoL;
  • RT: ↑ MS.
Møller
et al. [29]		10 patients (28–62 years old). Biopsy only from 6 patientsCombined: 3 times/wk, 90-min, 10 wk. A session of 6 resistance exe. at 1 RM (progressively increasing), 10 min break, and patients consumed a whey protein drink (360 kcal), plus group sessions on ergometer bicycles (progressively increasing intensity).Vastus lateralisBreast cancer (n = 7), head and neck cancer (n= 1), rectal cancer (n = 1), sarcoma (n = 1)Epirubicin and/or cyclophosphamide and/or doxorubicin/adramycin and/or carboplatin and/or vinorelbin/navelbine and/or flouroacil and/or trabectedin and/or gemcitabin
  • MS (performance evaluation);
  • fiber CSA;
  • biochemical markers of metabolic pathways;
  • satellite cell analysis.
  • ↓ type II fiber CSA during chemo., and ↑ with CT;
  • ↑ GLUT4 during chemo. and after exercise;
  • = AMPK and mitochondrial protein levels (Cyt-C, COX-IV, PDH, SDH, and VDAC);
  • ↓ FOXO3 after CT;
  • ↓ MuRF1 and atrogin-1 during chemo. and return to baseline after CT;
  • ↑ mTOR during chemo and return to baseline after CT.
Winters-Stone
et al. [38]		144 women ≥65 years old, divided into 3 groups: AET (n = 37), RET (n = 39) or FLEX (n = 38)Supervised for 12 months, for 60-min, 3 times/wk: AET: low-impact dance, progressed from 20 to 45 min and increasing from 35% to 65% of HRR*. RET: 10 exercises, 2–3 sets of 10–15 reps at RM, (progressively increasing); FLEX: Stretching and relaxation exercise, 2–3 reps, holding for 15–60 s;
Unsupervised for 6 months, with DVD-based version of their program, 3 times/wk.		Not availableBreast cancer stage I-III.≥2 years postchemotherapy and/or radiation therapy
  • Physical function (SPPB*);
  • physical fitness (6 MWD*);
  • MS;
  • flexibility.
  • AET and RET: ↑ physical performance;
  • AET and RET: ↑ MS;
  • RET: ↑ 6 MWD and SPPB;
  • RET and FLEX: ↑ flexibility;
  • RET unsupervised: ↑ lower extremity function.
*VO2max, maximal oxygen consumption (indicator of cardiovascular fitness and aerobic endurance); *RM, repetition maximum (maximum load a muscle group can overcame for a given number of repetitions) [39]; *RPE, rating of perceived exertion (on Borg Scale (0–20), measure how hard the activity is physically); *HRR, heart rate reserve (difference between your maximum heart rate and resting heart rate); *Muscular fatigue index: FI% = [(peak torque of initial three repetitions peak torque of final three repetitions)/peak torque of initial three repetitions] × 100, an adapted formula, described by Kannus [40]; *SPPB, Physical Performance Battery (3 timed performance tests scored 0–4. The scores are summed, where scores indicate better physical function and low scores on the SPPB (≤9) predict disability, hospitalization, nursing home admission, and mortality); *6MWD, 6 min walked distance (indicates mortality and morbidity in older adults and clinical populations); Abbreviations: 4E-BP1, Eukaryotic translation initiation factor 4E; ACC, Acetyl-CoA carboxylase; AET, aerobic exercise training; AMPK, AMP-activated protein kinase; ATG, Autophagy related; BW, Bodyweight; COX-IV, Cytochrome C Oxidase Subunit 4; CSA, cross-sectional area; CT, Combined training; Cyt-c, cytochrome c; DIA, diaphragm muscle; EDL, extensor digitorum longus; ET, endurance training; EXER, exercise group; Fbxo32/MAFbx, F-box only protein 32; Fis1, Fission 1; FLEX, flexibility; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; GLUT4, glucose transporter 4; HB, Home-based; IL-6, Interleukin-6; LC3B, Microtubule-associated protein 1A/1B-light chain 3; Mfn1/2, Mitofusin-1/2; MF, muscle fatigue; MNU, N-Nitroso-N-methylurea; MS, Muscle strength; mTOR, mammalian target of rapamycin; MuRF1, Muscle-specific RING finger protein 1; Myf, Myogenic factor; MyoD, Myogenic differentiation; NF-kB, Nuclear factor kappa-light-chain-enhancer of activated B cells; OXFU, Oxaliplatin; p62, Sequestosome-1; PGC-1α, Peroxisome proliferator-activated receptor-gamma coactivator; PDH, Pyruvate dehydrogenase; QoL, Quality of life; RDI, Relative dose intensity (measure chemotherapy completion rate); RET, Resistance exercise training; RT, resistance training; SAL, saline; SDH, Succinate dehydrogenase; STAT3, Signal transducer and activator of transcription 3 S6rp, Ribosomal protein S6; TG, triglyceride; TLR-4, Toll-like receptor 4; TM, Treadmill trained; TWEAK, TNF-related weak inducer of apoptosis; UC, usual care; ULK1, Unc-51-like kinase 1; VDAC, voltage-dependent anion channel; VO2peak, peak volume of oxygen consumed; ↑ increased; ↓ decreased.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Aires, I.; Duarte, J.A.; Vitorino, R.; Moreira-Gonçalves, D.; Oliveira, P.; Ferreira, R. Restoring Skeletal Muscle Health through Exercise in Breast Cancer Patients and after Receiving Chemotherapy. Int. J. Mol. Sci. 2024, 25, 7533. https://doi.org/10.3390/ijms25147533

AMA Style

Aires I, Duarte JA, Vitorino R, Moreira-Gonçalves D, Oliveira P, Ferreira R. Restoring Skeletal Muscle Health through Exercise in Breast Cancer Patients and after Receiving Chemotherapy. International Journal of Molecular Sciences. 2024; 25(14):7533. https://doi.org/10.3390/ijms25147533

Chicago/Turabian Style

Aires, Inês, José Alberto Duarte, Rui Vitorino, Daniel Moreira-Gonçalves, Paula Oliveira, and Rita Ferreira. 2024. "Restoring Skeletal Muscle Health through Exercise in Breast Cancer Patients and after Receiving Chemotherapy" International Journal of Molecular Sciences 25, no. 14: 7533. https://doi.org/10.3390/ijms25147533

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop